Surmodics, Inc. reiterated earnings guidance for the year 2022. For the year, the company expects revenue to range from $97 million to $101 million. Diluted GAAP EPS is expected to range from a loss per share of $2.05 to $1.55, which reflects increased investments to accelerate the Company's strategy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.06 USD | -0.10% | +22.34% | +15.71% |
May. 30 | Barrington Research Downgrades SurModics to Market Perform From Outperform | MT |
May. 29 | Needham Downgrades SurModics to Hold From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.71% | 600M | |
-7.16% | 178B | |
-1.23% | 107B | |
-4.86% | 67.04B | |
-4.28% | 47.23B | |
+10.32% | 44.62B | |
+8.14% | 42.5B | |
+15.53% | 25.22B | |
-5.88% | 24.14B | |
-5.38% | 23.69B |
- Stock Market
- Equities
- SRDX Stock
- News Surmodics, Inc.
- Surmodics, Inc. Reiterates Earnings Guidance for the Year 2022